The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.145
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.15 (7.246%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 2.145
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

26 Oct 2016 15:42

RNS Number : 5484N
Immupharma PLC
26 October 2016
 

RNS : FOR IMMEDIATE RELEASE

26 OCTOBER 2016

 

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

TR1 NOTIFICATION OF MAJOR INTEREST

 

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has received a TR-1 by Lanstead Capital LP ("Lanstead"). Lanstead's holding in ImmuPharma is now confirmed at a total of 10,521,555 Ordinary Shares which equates to a current position in the Company of 8.4%.

 

Full disclosure of the TR1 is shown below:

 

-Ends-

For further information please contact:

 

ImmuPharma plc (www.immupharma.org)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman

Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

 

+ 44 (0) 7721 413496

 

 

 

Panmure, Gordon & Co., (NOMAD & Broker)

 

+44 (0) 20 7886 2500

Freddy Crossley, Duncan Monteith, Corporate Finance

Charles Leigh-Pemberton, Corporate Broking

 

 

Northland Capital Partners Limited (Joint Broker)

Patrick Claridge, David Hignell, Corporate Finance

Rob Rees, John Howes, Corporate Broking

 

 

 

 

 

 

 

+44 (0)20 3861 6631

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Immupharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

x

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

The placement by ImmuPharma PLC of 2,857,143 new ordinary shares

x

3. Full name of person(s) subject to thenotification obligation: iii

Lanstead Capital LP

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

21 October 2016

6. Date on which issuer notified:

25 October 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

14%, 13%, 12%, 11%, 10%, 9%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB0033711010

17,893,456

17,893,456

10,521,555

10,521,555

8.44%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

N/A

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

N/A

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

10,521,555

8.44%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

N/A

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Lisa De Vargas, Lanstead Partners Limited

15. Contact telephone number:

+1 (801) 895-3700

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLZQLFLQBFXFBQ
Date   Source Headline
30th Apr 20207:00 amRNSFINAL RESULTS FOR THE 12M ENDED 31/12/19
6th Apr 20207:00 amRNSIMM live on Investor Meet Company platform 7 April
3rd Apr 20203:55 pmRNSHolding(s) in Company
2nd Apr 20208:26 amRNSHolding(s) in Company
31st Mar 202012:07 pmRNSSecond Price Monitoring Extn
31st Mar 202012:02 pmRNSPrice Monitoring Extension
30th Mar 20208:02 amRNS£1.5m Subscrip'n to fund R&D pipeline- replacement
30th Mar 20207:00 amRNS£1.5m Subscription to fund R&D pipeline expansion
20th Mar 20204:45 pmRNSSecond Price Monitoring Extn
20th Mar 20204:40 pmRNSPrice Monitoring Extension
18th Mar 20204:42 pmRNSSecond Price Monitoring Extn
18th Mar 20204:37 pmRNSPrice Monitoring Extension
16th Mar 20204:43 pmRNSSecond Price Monitoring Extn
16th Mar 20204:39 pmRNSPrice Monitoring Extension
4th Mar 20204:35 pmRNSPrice Monitoring Extension
28th Feb 20207:03 amRNSIncanthera plc – Admission to trading on NEX
21st Feb 20204:35 pmRNSPrice Monitoring Extension
17th Feb 20208:00 amRNSIncanthera announces Rule 23 Notice re NEX listing
12th Feb 20204:41 pmRNSSecond Price Monitoring Extn
12th Feb 20204:35 pmRNSPrice Monitoring Extension
6th Feb 20207:00 amRNSUpdate on the Avion Agreement
5th Feb 20204:40 pmRNSSecond Price Monitoring Extn
5th Feb 20204:35 pmRNSPrice Monitoring Extension
7th Jan 20204:40 pmRNSSecond Price Monitoring Extn
7th Jan 20204:35 pmRNSPrice Monitoring Extension
19th Dec 20194:35 pmRNSPrice Monitoring Extension
19th Dec 20197:00 amRNSAdmission today to trading on Euronext Growth
17th Dec 20197:00 amRNSPublication of Information Note (Euronext Growth)
13th Dec 20197:00 amRNSDual Listing on Euronext Growth Brussels
11th Dec 201912:49 pmRNSShare Price Volatility
3rd Dec 20197:00 amRNSIMMUPHARMA TO PRESENT AT BIOTECH SHOWCASET 2020
2nd Dec 20197:00 amRNSTR-1: notification of major holdings
28th Nov 20197:00 amRNSLicence Agreement for Lupuzor with Avion in US
25th Nov 20194:41 pmRNSSecond Price Monitoring Extn
25th Nov 20194:35 pmRNSPrice Monitoring Extension
5th Nov 20194:41 pmRNSSecond Price Monitoring Extn
5th Nov 20194:35 pmRNSPrice Monitoring Extension
7th Oct 201912:07 pmRNSSecond Price Monitoring Extn
7th Oct 201912:02 pmRNSPrice Monitoring Extension
4th Oct 201912:07 pmRNSSecond Price Monitoring Extn
4th Oct 201912:02 pmRNSPrice Monitoring Extension
1st Oct 20194:40 pmRNSSecond Price Monitoring Extn
1st Oct 20194:35 pmRNSPrice Monitoring Extension
30th Sep 20197:00 amRNSInterim Results Announcement
18th Sep 20194:35 pmRNSPrice Monitoring Extension
4th Jul 20197:00 amRNSTR-1: notification of major holdings
2nd Jul 20193:33 pmRNSTR-1: notification of major holdings
28th Jun 20197:00 amRNSUpdate on Lupuzor
27th Jun 20191:38 pmRNS2019 Annual General Meeting
26th Jun 20197:00 amRNSSubscription to raise £2.66 million

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.